Management of Proliferative Diabetic Retinopathy

Introduction to Treatment Guidelines

The American Academy of Ophthalmology recommends prompt treatment of proliferative diabetic retinopathy within less than 1 month of diagnosis 1, 2
The American Diabetes Association indicates that anti-VEGF therapy is non-inferior to traditional panretinal laser photocoagulation for reducing vision loss risk in PDR patients 3, 4, 5
Bevacizumab is an established anti-VEGF agent used for treating PDR and has demonstrated efficacy in regressing retinal neovascularization 2

Standard anti-VEGF protocols for PDR typically require intensive initial treatment with near-monthly injections during the first year, followed by maintenance dosing 4, 5
The FDA-approved regimen for aflibercept specifies 5 monthly loading injections followed by every-8-week maintenance, though bevacizumab dosing is often adapted from ranibizumab and aflibercept protocols 6
A 3-injection plan is insufficient because PDR patients treated with anti-VEGF therapy require a greater number of visits and treatments than panretinal laser alone 5

Initial intensive phase: Monthly bevacizumab injections (typically 1.25 mg) for at least 4-6 months with close monitoring 2
Maintenance phase: Extended interval dosing (every 6-8 weeks) based on clinical response and OCT findings 6
Monitoring schedule: Follow-up every 1-3 months to assess neovascularization regression and need for continued therapy 1, 2, 6

The underlying treatment (bevacizumab for PDR) is medically appropriate, with guidelines explicitly supporting anti-VEGF therapy for proliferative diabetic retinopathy 3, 4, 5
Certification as medically necessary allows for proper treatment while the inadequate 3-injection plan should be modified to reflect evidence-based dosing 6